Insider Selling: Humacyte, Inc. (NASDAQ:HUMA) Director Sells 5,182 Shares of Stock

Humacyte, Inc. (NASDAQ:HUMA) Director Kathleen Sebelius sold 5,182 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $5.40, for a total transaction of $27,982.80. Following the transaction, the director now owns 40,276 shares in the company, valued at $217,490.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Humacyte Trading Up 8.4 %

HUMA stock traded up $0.44 on Wednesday, reaching $5.69. The company’s stock had a trading volume of 2,675,583 shares, compared to its average volume of 2,200,491. The business has a fifty day simple moving average of $6.93 and a two-hundred day simple moving average of $5.53. Humacyte, Inc. has a 12-month low of $1.96 and a 12-month high of $9.97. The firm has a market cap of $677.59 million, a PE ratio of -5.69 and a beta of 1.47. The company has a debt-to-equity ratio of 0.61, a quick ratio of 5.41 and a current ratio of 5.41.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). As a group, research analysts forecast that Humacyte, Inc. will post -1.09 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on HUMA shares. Cantor Fitzgerald reissued an “overweight” rating and set a $7.00 price objective on shares of Humacyte in a research note on Tuesday, July 2nd. BTIG Research increased their price objective on Humacyte from $8.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, July 15th. EF Hutton Acquisition Co. I raised Humacyte to a “strong-buy” rating in a research note on Monday. Finally, Benchmark reissued a “buy” rating and set a $15.00 price objective on shares of Humacyte in a research note on Thursday, September 5th. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $8.60.

Institutional Trading of Humacyte

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company lifted its stake in Humacyte by 32.5% in the second quarter. The Manufacturers Life Insurance Company now owns 34,919 shares of the company’s stock worth $168,000 after acquiring an additional 8,557 shares during the period. Millennium Management LLC lifted its position in Humacyte by 504.3% during the second quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock valued at $7,677,000 after buying an additional 1,334,641 shares during the period. Deerfield Management Company L.P. Series C purchased a new position in Humacyte during the second quarter valued at $1,550,000. AQR Capital Management LLC lifted its position in Humacyte by 1,018.4% during the second quarter. AQR Capital Management LLC now owns 256,342 shares of the company’s stock valued at $1,230,000 after buying an additional 233,422 shares during the period. Finally, Marshall Wace LLP lifted its position in Humacyte by 3,301.5% during the second quarter. Marshall Wace LLP now owns 463,662 shares of the company’s stock valued at $2,226,000 after buying an additional 450,031 shares during the period. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.